



## NEONATAL Medication Monograph

# PALIVIZUMAB

This document should be read in conjunction with this [DISCLAIMER](#)

**Highly Restricted:** Requires Neonatologist or Microbiologist approval before commencing

<b>Presentation</b>	<b>Vial:</b> 50mg/0.5mL 100mg/mL Ready to Use Vial
<b>Description</b>	Humanised IgG, anti RSV monoclonal antibody.
<b>Indications</b>	<p>For immunoprophylaxis against severe Respiratory Syncytial Virus (RSV) lower respiratory tract infections in high risk infants during months of increased incidence of the virus and in patients 4 weeks of age and any of the following criteria:</p> <ul style="list-style-type: none"><li>• Born <math>\leq 28</math> weeks gestational with chronic lung disease defined as needing supplemental oxygen, ventilation or CPAP at 28 days of life.</li><li>• All indigenous neonates born <math>\leq 28</math> weeks gestational</li><li>• Neonates with hemodynamically significant congenital heart disease</li><li>• Neonates having undergone a major surgical procedure and requiring prolonged hospitalisation</li></ul> <p><b>NOTE: Parent/Guardian consent is to be obtained prior to administration of Palivizumab</b></p>
<b>Contraindications</b>	Hypersensitivity to humanised monoclonal antibodies.
<b>Precautions</b>	Moderate to severe acute infection or febrile illness; thrombocytopenia
<b>Dosage</b>	<b>IM:</b> 15mg/ kg/ dose  Repeat dose monthly during RSV season (usually May-October). Supplemental dose may be required following cardiac surgery.

<b>Adverse Reactions</b>	<b>Common:</b> Induration and swelling at injection site. Upper respiratory tract infection, otitis media, fever, rhinitis, rash, cough, diarrhoea, wheeze, cyanosis, arrhythmia in patients with congenital heart disease
	<b>Serious:</b> Anaphylaxis and hypersensitivity reactions
<b>Compatible Fluids</b>	Do not add any diluent to the liquid solution
<b>Preparation</b>	Available from CIVAS (KEMH & PCH) No Reconstitution required. Do not Shake the vial
<b>Administration</b>	<b>IM:</b> In the anterolateral aspect of the thigh Give injection volumes > 1mL in divided doses
<b>Monitoring</b>	Observe injection site for induration and swelling
<b>Storage</b>	Palivizumab vials should be stored in a refrigerator at 2° to 8oC. Do not freeze.
<b>Notes</b>	Do not re-enter vial after initial withdrawal and discard any unused portions. Use one dose per vial Administer as soon as possible after withdrawal from the vial.
<b>Related clinical guidelines</b>	<a href="#">Neonatal Viral Infections</a>

<b>References</b>	<p>Society of Hospital Pharmacists of Australia. Palivizumab . In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2020 [cited 2020 Sep 04]. Available from: <a href="http://aidh.hcn.com.au">http://aidh.hcn.com.au</a></p> <p>Murray J, Saxena S, Sharland M. Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals. <i>Arch Dis Child</i>. 2014;99(5):469-473. doi:10.1136/archdischild-2013-303764</p> <p>Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection PEDIATRICS Volume 134, Number 2, August 2014 <a href="http://pediatrics.aappublications.org/content/134/2/415.full.html">http://pediatrics.aappublications.org/content/134/2/415.full.html</a></p> <p>Palivizumab for RSV prophylaxis in high risk paediatric patients. Children's Health Queensland Hospital and Health Service Guideline</p>
-------------------	---

Keywords:	Palivizumab, RSV, Respiratory Syncytial Virus		
Publishing:	<input checked="" type="checkbox"/> Intranet	<input checked="" type="checkbox"/> Internet	
Document owner:	Head of Department - Neonatology		
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate		
Date first issued:	October 2008	Version:	3.0
Last reviewed:	September 2020	Next review date:	September 2023
Endorsed by:	Neonatal Directorate Management Group	Date:	September 2020
Standards Applicable:	NSQHS Standards: 1  , 3  , 4  , 8  Acute Deterioration		
<p><b>Printed or personally saved electronic copies of this document are considered uncontrolled.</b></p> <p><b>Access the current version from the WNHS website.</b></p> <p><b>For any enquiries relating to this guideline, please email <a href="mailto:KEMH.PharmacyAdmin@health.wa.gov.au">KEMH.PharmacyAdmin@health.wa.gov.au</a></b></p>			

© Department of Health Western Australia 2019